Literature DB >> 20719986

Serological protection induced by Haemophilus influenzae Type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed?

Romeo S Rodriguez1, Cesar Mascarenas, Carlos J Conde-Glez, Jaime Inostroza, Sonia Villanueva, María Elena Velázquez, Miguel Angel Sánchez-Alemán, Gabriela Echániz.   

Abstract

We determined the seroprevalence of protective antibodies against Hib in Mexican children under the age of five using a standardized enzyme-linked immunosorbent assay. Hib antibodies (≥ 0.15 μg/ml) were present in 95.34% (±1.14% [seroprevalence ± standard error]) of samples. Fewer children aged 30 to 47 months had protective Hib antibody levels (91.45% ± 2.60%) than children from 12 to 29 and 48 to 59 months (97.3% ± 1.34% and 97.44% ± 1.80%, respectively).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20719986      PMCID： PMC2953005          DOI： 10.1128/CVI.00249-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  25 in total

1.  Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data.

Authors:  Heikki Peltola; Eeva Salo; Harri Saxén
Journal:  BMJ       Date:  2004-11-25

2.  Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland.

Authors:  Margaret Fitzgerald; Melissa Canny; Darina O'Flanagan
Journal:  Euro Surveill       Date:  2005-09-29

3.  [Increase in the number of invasive Haemophilus influenzae type b infections].

Authors:  L Spanjaard; S van den Hof; H E de Melker; P E Vermeer-de Bondt; A van der Ende; G T Rijkers
Journal:  Ned Tijdschr Geneeskd       Date:  2005-12-03

4.  Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.

Authors:  R M Carlsson; B A Claesson; U Selstam; E Fagerlund; M Granström; C Blondeau; A Hoffenbach
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

5.  Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study.

Authors:  Richard A Adegbola; Ousman Secka; George Lahai; Nellie Lloyd-Evans; Alpha Njie; Stanley Usen; Claire Oluwalana; Stephen Obaro; Martin Weber; Tumani Corrah; Kim Mulholland; Keith McAdam; Brian Greenwood; Paul J M Milligan
Journal:  Lancet       Date:  2005 Jul 9-15       Impact factor: 79.321

6.  Increase in genetic diversity of Haemophilus influenzae serotype b (Hib) strains after introduction of Hib vaccination in The Netherlands.

Authors:  Leo M Schouls; Arie van der Ende; Ingrid van de Pol; Corrie Schot; Lodewijk Spanjaard; Paul Vauterin; Dorus Wilderbeek; Sandra Witteveen
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

7.  Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany.

Authors:  Helen Kalies; Thomas Verstraeten; Veit Grote; Nicole Meyer; Anette Siedler; Heinz-Josef Schmitt; Thomas Breuer; Lawrence H Moulton; Rüdiger von Kries
Journal:  Pediatr Infect Dis J       Date:  2004-10       Impact factor: 2.129

8.  Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine.

Authors:  T V Murphy; P Pastor; F Medley; M T Osterholm; D M Granoff
Journal:  J Pediatr       Date:  1993-04       Impact factor: 4.406

9.  Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination.

Authors:  T V Murphy; K E White; P Pastor; L Gabriel; F Medley; D M Granoff; M T Osterholm
Journal:  JAMA       Date:  1993-01-13       Impact factor: 56.272

10.  [Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded programm on immunization in Chile].

Authors:  Pablo Cruces R; Alejandro Donoso F; Jorge Camacho A; Marcela Llorente H
Journal:  Rev Chilena Infectol       Date:  2006-02-02       Impact factor: 0.520
View more
  5 in total

1.  Impact of routine vaccination against Haemophilus influenzae type b in The Gambia: 20 years after its introduction.

Authors:  Syed Ma Zaman; Stephen Rc Howie; Magnus Ochoge; Ousman Secka; Alasana Bah; Ignatius Baldeh; Bakary Sanneh; Saffiatou Darboe; Buntung Ceesay; Haddy Bah Camara; Fatme Mawas; Malick Ndiaye; Ilias Hossain; Rasheed Salaudeen; Kalifa Bojang; Samba Ceesay; Dawda Sowe; M Jahangir Hossain; Kim Mulholland; Brenda A Kwambana-Adams; Catherine Okoi; Siaka Badjie; Lamin Ceesay; Jason M Mwenda; Adam L Cohen; Mary Agocs; Richard Mihigo; Christian Bottomley; Martin Antonio; Grant A Mackenzie
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

Review 2.  Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use.

Authors:  M P E Slack; A W Cripps; K Grimwood; G A Mackenzie; M Ulanova
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

3.  Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study.

Authors:  Laura L Hammitt; Rosie J Crane; Angela Karani; Alex Mutuku; Susan C Morpeth; Polly Burbidge; David Goldblatt; Tatu Kamau; Shahnaaz Sharif; Neema Mturi; J Anthony G Scott
Journal:  Lancet Glob Health       Date:  2016-02-05       Impact factor: 38.927

4.  Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b.

Authors:  Nadia A Charania; Seyed M Moghadas
Journal:  BMC Public Health       Date:  2017-09-13       Impact factor: 3.295

5.  Immune responses to vaccine-preventable diseases among toddlers and preschool children after primary immunization and first booster in Northwestern Algiers, Algeria.

Authors:  Nabila Benamrouche; Hassiba Tali Maamar; Samia Chemli; Houria Senouci; Kheira Rahal
Journal:  Heliyon       Date:  2018-06-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.